CP-481,715 Nickel Allergy Study.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00141180
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : July 25, 2006
Information provided by:

Brief Summary:
To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Condition or disease Intervention/treatment Phase
Dermatitis, Allergic Contact Drug: CP-481,715 Phase 1

Study Type : Interventional  (Clinical Trial)
Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.
Study Start Date : September 2003
Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Nickel
U.S. FDA Resources

Primary Outcome Measures :
  1. Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST.

Exclusion Criteria:

  • Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00141180

United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-0314
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10032
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78759
Pfizer Investigational Site
Bryan, Texas, United States, 77802
Pfizer Investigational Site
Hellerup, Denmark, 2900
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer Identifier: NCT00141180     History of Changes
Other Study ID Numbers: A3081018
First Posted: September 1, 2005    Key Record Dates
Last Update Posted: July 25, 2006
Last Verified: November 2005

Additional relevant MeSH terms:
Dermatitis, Allergic Contact
Skin Diseases
Dermatitis, Contact
Skin Diseases, Eczematous
Hypersensitivity, Delayed
Immune System Diseases
Trace Elements
Growth Substances
Physiological Effects of Drugs